This page uses content from Wikipedia and is licensed under CC BY-SA.

Enfortumab vedotin

Enfortumab vedotin
Monoclonal antibody
Clinical data
Other namesAGS-22ME
ATC code
  • none
CAS Number
  • none
Chemical and physical data
Molar mass149.0 kg/mol g·mol−1

Enfortumab vedotin[1] (ASG-22ME) is an antibody-drug conjugate[2] designed for the treatment of cancer expressing Nectin-4.[3] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.

The fully humanized antibody was created by scientists at Agensys (part of Astellas) using Xenomice from Amgen; the linker technology holding the antibody and the toxin together was provided by and licensed from Seattle Genetics.[4]

Results of a phase I clinical trial were reported in 2016.[2]


  1. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
  2. ^ a b Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress. Oct 2016
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Enfortumab Vedotin, American Medical Association.
  4. ^ Challita-Eid, PM; et al. (15 May 2016). "Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models". Cancer Research. 76 (10): 3003–13. doi:10.1158/0008-5472.can-15-1313. PMID 27013195.